DESTINY TRIAL (Inspiron x Biomatrix)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2013 by Scitech Produtos Medicos Ltda
Sponsor:
Information provided by (Responsible Party):
Scitech Produtos Medicos Ltda
ClinicalTrials.gov Identifier:
NCT01856088
First received: December 27, 2012
Last updated: June 24, 2013
Last verified: May 2013
  Purpose

The main objective of this study is to evaluate the effectiveness of stent Inspiron ™ sirolimus-eluting and coating the abluminal biodegradable stent Biomatrix Flex ™ lesions in native coronary arteries.


Condition Intervention Phase
Coronary Artery Disease
Device: Inspiron ™ stent eluting sirolimus or Biomatrix™ stent eluting biolimus
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Stents Coated With the Biodegradable Polymer on Their Faces and Elution of Sirolimus Abluminais Versus Elution Biolimus for the Treatment of Coronary Lesions Again - Randomized Destiny

Resource links provided by NLM:


Further study details as provided by Scitech Produtos Medicos Ltda:

Primary Outcome Measures:
  • Lumen Loss [ Time Frame: 9 months after the procedure ] [ Designated as safety issue: Yes ]

    For an accurate assessment of the stent conditions 9 months after implantation, a follow-up catheterization will be performed at the 9 months visit in order to measure the diameter of the artery at the stented site.

    A subgroup of 60 patients will be evaluated with volumetric intravascular ultrasound at 9 months. Also, a subgroup of 21 patients will be evaluated with optical coherence tomography at the end of the index procedure and 9 months.



Secondary Outcome Measures:
  • Adverse Cardiac Events [ Time Frame: 30 days, 4, 9, 12 months and 2, 3, 4, 5 years after the procedure. ] [ Designated as safety issue: Yes ]
    The clinical follow-up should be performed during the index procedure at 30 days, 4, 9, 12 months and 2, 3, 4, 5 years after the procedure, and should consist of an assessment of the angina status (according to the Canadian Cardiovascular Society Classification and the Braunwald for unstable angina) and major adverse cardiac avents and any interventional treatment (e.g: repeated targetlesion revascularization or recurrent ischemia)


Estimated Enrollment: 165
Study Start Date: May 2013
Estimated Study Completion Date: February 2018
Estimated Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Drug Eluting Stent
Stent Inspiron with Sirolimus
Device: Inspiron ™ stent eluting sirolimus or Biomatrix™ stent eluting biolimus
Site preparation acces should be performed as per standard hospital procedures It is recommended to cross the target lesion with 0,014 inch exchange-lenght guide wire. If necessary the involved lesion should be predilated with appropriately sized balloons using standard techniques. It is strongly encouraged that the Investigators use similar materials and techniques throughout the study to maintain consistency and standardization of care. A stent consists of an endovascular prosthesis with a metalic mesh structure that is implanted at the site of the artery blockage via catheterization procedure. The objective of stenting is to obtain an angiographic appearance of the expanded stent only outside the limits of the target vessel filled with contrast medium.
Other Names:
  • Drug eluting stent
  • Angiography
Active Comparator: Drug eluting stent
Stent Biomatrix Flex with biolimus
Device: Inspiron ™ stent eluting sirolimus or Biomatrix™ stent eluting biolimus
Site preparation acces should be performed as per standard hospital procedures It is recommended to cross the target lesion with 0,014 inch exchange-lenght guide wire. If necessary the involved lesion should be predilated with appropriately sized balloons using standard techniques. It is strongly encouraged that the Investigators use similar materials and techniques throughout the study to maintain consistency and standardization of care. A stent consists of an endovascular prosthesis with a metalic mesh structure that is implanted at the site of the artery blockage via catheterization procedure. The objective of stenting is to obtain an angiographic appearance of the expanded stent only outside the limits of the target vessel filled with contrast medium.
Other Names:
  • Drug eluting stent
  • Angiography

Detailed Description:

This is a study of non-inferiority, multicentre, prospective, randomized into two treatment arms: I) Inspiron ™ stent eluting sirolimus or II) ™ Biomatrix stent eluting biolimus. Are a total of 165 randomized patients.

Patients will be followed for 60 months after the procedure. All new patients will be undergoing angiography for evaluation at 9 months. A subgroup of 60 patients will be evaluated with volumetric intravascular ultrasound at 9 months. Also, a subgroup of 21 patients will be evaluated with optical coherence tomography at the end of the index procedure and 9 months. It is anticipated that the total study duration is 72 months: 12 months to complete the admission of patients and 60 months of follow-up.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age > 18 years;
  2. Symptomatic ischemic heart disease and / or objective evidence of myocardial ischemia with one or two target lesions located in different epicardial vessels;
  3. A(s) lesion(s) to target(m) must be:

    1. Again (not restenotic);
    2. Located in a native coronary artery diameter from 2.5 to 3.5 mm (visual);
    3. Can be treated with a single stent up to 29 mm in length;
    4. Obstruction with stenosis > 50% diameter (visual);
  4. Acceptable candidate for CABG;
  5. The patient will be informed of the nature of the study, agree with their rules and provide a written informed consent approved by the local Ethics Committee.

Exclusion Criteria:

  1. Women of childbearing age with no history of surgical sterilization;
  2. Myocardial infarction with Q wave occurred in the last 48 hours before the index procedure;
  3. Myocardial infarction with or without Q wave with cardiac markers even at high levels;
  4. Ejection fraction < 30%;
  5. Impaired renal function (creatinine> 2.0 mg / dl) or calculated creatinine clearance < 60 ml / min;
  6. Platelet count <100,000 cells/mm3 or > 700,000 cells/mm3;
  7. Total leukocyte count <3000 cells/mm3;
  8. Documented or suspected liver disease (including laboratory evidence of hepatitis);
  9. Heart transplant recipient;
  10. Known allergies to aspirin, clopidogrel, ticlopidine, paclitaxel, sirolimus, heparin or stainless steel;
  11. Patient with a life expectancy less than 12 months;
  12. Any significant medical condition which in the opinion of the investigator would interfere with the ideal of patient participation in this study;
  13. Participation in other research in the last 12 months, unless there is direct benefit to the research subject;
  14. Coronary angioplasty (with or without stenting) for less than 6 months anywhere in the target vessel;
  15. Coronary angioplasty (with or without stenting) prior to any time in that segment Diste less than 5 mm (proximal or distal) of the lesion;
  16. Coronary angioplasty (with or without stenting) scheduled in the first 12 months after the index procedure in any segment of the target vessel.

EXCLUSION CRITERIA angiographic

  1. Restenotic target lesion;
  2. Need for treatment for more than one lesion in the same vessel;
  3. Need for treatment with three or more lesions in the same procedure;
  4. Target vessel diameter <2.5 mm or> 3.5 mm (visual);
  5. Target lesion long not susceptible to treatment with a single stent to 29mm in length, according to the judgment of the operator;
  6. Lesion of the coronary artery unprotected ( > 50% stenosis);
  7. Angiographic thrombus;
  8. Target lesion in surgical graft;
  9. Total occlusion (TIMI anterograde flow 0 or 1);
  10. Ostial lesion;
  11. The target lesion bifurcation with side branch that may require intervention during the procedure, with or without stenting;
  12. Injuries that are impossible to anticipate predilatation successfully or that is necessary to use rotablator;
  13. The target vessel with excessive tortuosity.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01856088

Contacts
Contact: Adriana Gouveia, nursing 55 11 98920-2999 adriana.gouveia@cmsmedical.com.br
Contact: Patricia Pereira, Medicine 55 11 2661 5368 patricia.pereira@incor.usp.br

Locations
Brazil
Hospital Santa Izabel Recruiting
Salvador, Bahia, Brazil
Contact: Aline de Souza Bernardes Reis    55 71 2203-8476    npcardio@yahoo.com   
Principal Investigator: Adriano Dourado, Medicine         
Intercath Meridional Recruiting
Cariacica, ES, Brazil
Contact: Ana Paula Oliveira    55 27 3346-2121    anapaula@intercath.com.br   
Principal Investigator: Bruno Moulin Machado, Medicine         
Encore - Cardiologia e Radiologia Intervencionista Recruiting
Goiânia, Goiás, Brazil
Contact: Mara Rubia Rocha    55 62 3230-1825    pesquisaclinica@encore.med.br   
Principal Investigator: Mauricio Prudete, Medicine         
Hospital Cardiologico Costantini Recruiting
Curitiba, PR, Brazil
Contact: Danilo , Nursing    55 41 3013-9266    pesquisa@hospitalcostantini.com.br   
Principal Investigator: Costantino Costantino, Medicine         
Instituto de Cardiologia do Rio Grande do Sul Recruiting
Porto Alegre, Rio Grande do Sul, Brazil
Contact: Antonieta Moraes, Nursing    55 51 3230-3678    pesquisaclinica@cardiologia.org.br   
Contact: Silvia , Nursing    55 51 3230-3678    pesquisaclinica@cardiologia.org.br   
Principal Investigator: Rogério E. Gomes Sarmento Leite, Medicine         
Instituto de Assistência Médica ao Servidor Publico Estadual Recruiting
São Paulo, SP, Brazil
Contact: Emilia Mizuno, Nursing    55 11 50837001    emiliamizuno@yahoo.com.br   
Principal Investigator: George Ximenes Meireles, Medicine         
Instituto Dante Pazzanese de Cardiologia Recruiting
São Paulo, SP, Brazil
Contact: Renata Viana, Medicine    55 11 5085-6325    rviana@dantepazzanese.org.br   
Principal Investigator: Alexandre Abizaid, Medicine         
Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da USP Recruiting
São Paulo, SP, Brazil
Contact: Patricia Pereira, Biomedicine    55 11 2661-5377    patricia.pereira@incor.usp.br   
Principal Investigator: Expedito E. Ribeiro da Silva, Medicine         
Santa Casa de Misericórdia de São Paulo Recruiting
São Paulo, SP, Brazil
Contact: José Mariani Júnior, Medicine    55 11 2176-7000    marianijr@uol.com.br   
Principal Investigator: José Mariani Júnior, Medicine         
Hospital Bandeirantes de São Paulo Recruiting
São Paulo, SP, Brazil
Contact: Sandra Regina Bardel, nursing    55 11 3345-2476    s.baradel@yahoo.com.br   
Contact: Stefania Rodrigues Pereira, Nursing    55 11 3345-2476    stefaniaenfermagem@hotmail.com   
Principal Investigator: Marcelo Cantarelli, Medicine         
Sub-Investigator: Helio Castello, Medicine         
Hospital Santa Marcelina Recruiting
São Paulo, Brazil
Contact: Stephanie Kitze         
Principal Investigator: Marco Antonio Perin         
Sponsors and Collaborators
Scitech Produtos Medicos Ltda
Investigators
Principal Investigator: Pedro Lemos Instituto do Coração - Incor
  More Information

Additional Information:
No publications provided

Responsible Party: Scitech Produtos Medicos Ltda
ClinicalTrials.gov Identifier: NCT01856088     History of Changes
Other Study ID Numbers: Scitech 004
Study First Received: December 27, 2012
Last Updated: June 24, 2013
Health Authority: Brazil: Ethics Committee

Keywords provided by Scitech Produtos Medicos Ltda:
Coronary artery
Drug eluting stent
thrombosis

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Sirolimus
Everolimus
Antibiotics, Antineoplastic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Antifungal Agents
Anti-Infective Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Anti-Bacterial Agents

ClinicalTrials.gov processed this record on July 24, 2014